text: Yo, patient recruitment's a challenge, no lie,
  Especially in rare disease trials, oh my!
  We gotta save time and resources, no doubt,
  So let's consider an inferential seamless route.
  
  Phase II/III design, that's the plan,
  For this rare disease trial, we'll take a stand.
  Two doses and a placebo, that's the game,
  Phase II's where we'll evaluate the aim.
  
  Based on intermediate results, we'll see,
  If more patients should join this clinical spree.
  Two doses and control, or just one we'll pick,
  Or maybe none at all, that'll do the trick.
  
  All patients, selected or not, will be,
  Followed closely for phase III, you see.
  Primary and secondary endpoints at stage two,
  In the final analysis, they'll all come through.
  
  Type I error rate, we'll keep it in check,
  If we apply the same level, no disrespect.
  Whether we test the dose effect, you know,
  With stage I data only, or combined, let's go.
  
  For multiplicity adjustments, we'll make a plan,
  Graphical testing procedure, that's the span.
  Two doses, two endpoints, gotta control,
  Type I error rate, we won't let it roll.
  
  And hey, for power calculation, listen up,
  We got an imputation approach, yup.
  Conditional power at stage I, no fuss,
  Sample size adaptive design, a must.
  
  Simulations, we'll run 'em, different settings,
  To compare approaches, see what they're getting.
  This trial example, it's our illustration,
  For the methods' applications, no hesitation.